Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RepHresh Pro-B

This article was originally published in The Tan Sheet

Executive Summary

Lil' Drug Store expands its RepHresh OTC women's health care offering with RepHresh Pro-B probiotic product, which contains the "only isolated vaginal lactobacillus strain that blocks and eliminates yeast and bacteria to help maintain feminine health," the firm announces at the National Association of Chain Drug Stores' Marketplace trade show in Boston June 23-26. The probiotics are encased in a capsule employing a polysaccharide matrix to protect the organisms during the digestive process until they reach the proper pH levels in the body, Cedar Rapids, Iowa-based firm says. The product will begin shipping to food, drug and mass retailers in mid-August, pending FDA approval of its New Dietary Ingredient notification, and a 30-count bottle of capsules will carry an SRP of $29.99, the firm says...

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

Topics

UsernamePublicRestriction

Register

PS100716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel